Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma
NCT04829097
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Glioblastoma
Interventions
COMBINATION_PRODUCT:
Temozolomide
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School